Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Ceftolozane Sulfate

If you want to know more about the Ceftolozane Sulfate, the following articles will give you some help. These news is the latest market situation, trend in development, or related tips of the Ceftolozane Sulfate industry. More news about Ceftolozane Sulfate, are being released. Follow us / contact us for more Ceftolozane Sulfate information!
  • Drug Patent & Exclusivity Expiration Report - Week of Dec 16 2024

    Drug Patent & Exclusivity Expiration Report - Week of Dec 16 2024

    2024-12-16

    This week, there are 16 drugs in the patent and exclusivity list. They are: - UNITED THERAPEUTICS CORP's REMODULIN, containing active ingredient TREPROSTINIL - VALINOR PHARMA LLC's MOVANTIK, containing active ingredient NALOXEGOL OXALATE - OTSUKA PHARMACEUTICAL CO LTD's ABILIFY, containing active ingredient ARIPIPRAZOLE - INTRA-CELLULAR THERAPIES INC's CAPLYTA, containing active ingredient LUMATEPERONE TOSYLATE - PFIZER INC's TOVIAZ, containing active ingredient FESOTERODINE FUMARATE - CUBIST PHARMACEUTICALS LLC's ZERBAXA, containing active ingredient CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - EISAI INC's LENVIMA, containing active ingredient LENVATINIB MESYLATE - PF PRISM CV's BOSULIF, containing active ingredient BOSUTINIB MONOHYDRATE - AMGEN INC's OTEZLA, containing active ingredient APREMILAST Read More